ERO1A and breast carcinoma: Notably, we found that high expression of NFIB and the combined signature of ERO1A and NFIB in patients with breast cancer of the basal‐like subtype were predictive of decreased distant metastasis‐free survival and/or overall survival (Fig 6D and E; Appendix Fig S7E and F).